Dendreon (DNDN) Completes Submission of Amended Biologics License Application for PROVENGE®
More News related to DNDN
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Dendreon Receives FDA Acknowledgement of Complete Response
- Leerink Says Takeaway From Dendreon's (DNDN) Q3 Report is the Busy Preparations for Provenge
- Dendreon (DNDN) Reports Q3 Loss of $0.40, Misses by 19c
- Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Dendreon Corporation (Nasdaq: DNDN) today announced that it has completed the submission of the amended Biologics License Application for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S. FDA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer. If approved by the FDA, PROVENGE would represent the first product in the new therapeutic class known as active cellular immunotherapies.
The amended BLA includes data from the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC.
"With the BLA submission complete, we have taken an important step towards reaching our goal of bringing a new therapy to men with advanced prostate cancer," said Mitchell H. Gold, MD, president and chief executive officer of Dendreon. "We look forward to working with the FDA to potentially make PROVENGE the first active cellular immunotherapy to be licensed in the United States."
Related Categories
Corporate NewsFDA
Hot List
Stocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
